Is VOYA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on The stop-loss repricing cycle, with revenue (ttm) at ~$8.17B. The bear case rests on medical stop-loss claims are reported and reserved on a policy-year basis with most policies renewing in January, so a bad trend surfaces in concentrated bursts rather than gradually, and the ~$91 million of adverse prior-year development booked in the first half of 2026 shows the reserve estimate can still move against the company. Analysts covering it are spread from $90.00 to $125.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Medical stop-loss claims are reported and reserved on a policy-year basis with most policies renewing in January, so a bad trend surfaces in concentrated bursts rather than gradually, and the ~$91 million of adverse prior-year development booked in the first half of 2026 shows the reserve estimate can still move against the company. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $90.00, -10.5% from the $100.56 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

The stop-loss repricing cycle. Voya has spent three renewal seasons raising stop-loss prices and walking away from business it does not want, which is why annualized in-force premiums and fees of ~$3.59 billion were roughly flat year over year while margins moved. The most optimistic analyst target on VOYA is $125.00, +24.3% from the $100.56 price. That figure is only reachable if this thesis works close to its best case.

Medical stop-loss claims are reported and reserved on a policy-year basis with most policies renewing in January, so a bad trend surfaces in concentrated bursts rather than gradually, and the ~$91 million of adverse prior-year development booked in the first half of 2026 shows the reserve estimate can still move against the company. Roughly half of quarterly operating earnings come from fee-based revenue tied to market levels, meaning a sustained equity drawdown reduces both Retirement and Investment Management earnings at the same time. Alternative investment income has been a recurring drag, costing ~$15 million pre-tax in the second quarter of 2026 alone. The TOMS Capital referendum has no binding legal effect and the board is under no obligation to act on it, so any part of the current share price that reflects sale expectations rests on an outcome nobody has agreed to. Separately, Voya is a defendant in Ravarino, et al. v. Voya Financial, Inc. (D. Conn., No. 3:21-cv-01658, filed December 14, 2021), a putative ERISA class action over the administration of its own 401(k) plan in which plaintiffs filed an amended complaint on December 10, 2025; this is a fiduciary-duty case, not a securities-fraud action, and the company disclosed an accrual of up to approximately $25 million for certain matters. The most pessimistic published target is $90.00, -10.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Runs workplace retirement plans, employee benefits including medical stop-loss insurance, and Voya Investment Management's asset platform.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (The stop-loss repricing cycle) stalling in the reported numbers rather than in the narrative, the risk above (medical stop-loss claims are reported and reserved on a policy-year basis with most policies renewing in January, so a bad trend surfaces in concentrated bursts rather than gradually, and the ~$91 million of adverse prior-year development booked in the first half of 2026 shows the reserve estimate can still move against the company) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

It runs three businesses. Retirement administers defined contribution plans for approximately 45,000 US employers covering more than ~10 million participant accounts. Voya Investment Management runs ~$377 billion of assets for institutions and funds. Employee Benefits underwrites group life, disability, voluntary products and medical stop-loss insurance sold through workplaces.

After-tax adjusted operating earnings were ~$140 million, or ~$1.51 per share, against ~$240 million and ~$2.46 a year earlier. Three items explain most of it: ~$40 million of pre-tax severance from an efficiency program, a ~$15 million pre-tax loss on alternative investments, and less favorable stop-loss and voluntary claims development than the unusually good prior-year quarter.

Stop-loss insurance covers self-funded employer health plans against claims above a set threshold. It is Voya's largest employee benefits product at ~$1.54 billion of annualized in-force premium. Because claims are lumpy and reserved by policy year, a single bad year shows up as adverse development months later, which is why the loss ratio has repeatedly moved the stock.